Single Agent Weekly Paclitaxel as Neoadjuvant Chemotherapy in Locally Advanced Breast Cancer: A Feasibility Study

The regimen of weekly single agent paclitaxel is feasible in patients with locally advanced breast cancer with acceptable toxicity. It resulted in a pathological response rate that was comparable with other regimens in this group of advanced stage patients. Considering the efficacy and low toxicity of this regimen, it is worth exploring in larger studies.